Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALXN2080 in Healthy Participants
NCT05428696Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zoracopan in paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and Complement 3 glomerulopathy (C3G) (10 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Number of Participants Reporting Treatment-Emergent Adverse Events and Number of Participants Reporting Serious Adverse Events. Started Sep 2022; status: completed.
02
Drugs
Zoracopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on NCT05428696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428696.